EUCTR2012-003155-11-IT进行中（未招募）不适用
Radiometabolic treatment with 90Y-DOTA0-Tyr3]-octreotide (90Y-DOTATOC) or[90Y-DOTA0-Tyr3-Thr8]-octreotate (90Y-DOTATATE)in tumours expressing somatostatin receptors - Yttrium-90-01
AZ. USL DI CESENA0 个研究点开始时间: 2012年8月9日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- male and female;> 18 years old, proven diagnosis of NET;progression of disease; no other valid therapeutic options available; adequate hematological, renal, hepatic parameters; measurable disease according to RECIST 1.1; no other anticancer treatments within 30 days (somatostatine analogs are permitted; informed consent signed by patients
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 75
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •no pregnancy or lactation; medullary invasion >= 50%; no previous emibody RT, ECOG PS > 2;life expectancy < 6 months
研究者
相似试验
进行中（未招募）
不适用
Receptorial radiotherapy with 177Lu-DOTA-Tyr3-Octreotate as Maintaining Therapy in Extended Small Cell Lung Cancer (SCLC) after a first standard chemotherapy line - IRST162.02oncological patientsMedDRA version: 12.1Level: LLTClassification code 10026532Term: Malignant neoplasm of thoraxEUCTR2010-018333-21-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
进行中（未招募）
1 期
PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH 90Y-DOTATOC IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL AND MANTLE CELL LYMPHOMASRelapsed or refractory DLBCL (DIFFUSE LARGE B CELL LYMPHOMAS) or MCL (MANTLE CELL LYMPHOMAS)MedDRA version: 17.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 17.0Level: HLTClassification code 10026798Term: Mantle cell lymphomasSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2014-003418-10-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI IRST - IRCCS35
进行中（未招募）
不适用
Receptor radionuclide therapy with [177Lu-DOTA]0,Tyr3-octreotate (177Lu-DOTATATE): a phase II trial. - NDcancer patientsMedDRA version: 9.1Level: LLTClassification code 10028980Term: NeoplasmEUCTR2007-005517-20-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
招募中
1 期
Therapy with radiopharmaceutical 177Lu-DOTATOC (177Lu-edotreotide or 177Lu-octreotide) in patients with diagnosis of somatostatin receptor positive tumor: a multicenter, prospective phase 2 studyPatients must have histologically or cytologically confirmation of neuroendocrine tumors or any other tumor histotype documented as sst-positiveMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2023-000086-14-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS268
进行中（未招募）
1 期
Therapy with radiopharmaceutical for the treatment of tumorseuroendocrine tumors in progression of disease and not suitable to additional treatments, positive to SSTRMedDRA version: 20.0Level: PTClassification code 10057270Term: Neuroendocrine carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003268-11-ITISTITUTO EUROPEO DI ONCOLOGIA29